img

Global Non-Hodgkin Lymphoma Treatment Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Non-Hodgkin Lymphoma Treatment Market Insights, Forecast to 2034

Non-Hodgkin’s lymphomas are one of the most commonly occurring cases of lymphomas and hence is also one of the most commonly occurring cancers. If not treated effectively, it is potentially lethal and leads to a shorter life span of the individuals diagnosed.
Market Analysis and InsightsGlobal Non-Hodgkin Lymphoma Treatment Market
Global Non-Hodgkin Lymphoma Treatment market is expected to reach to US$ 8443 million in 2024, with a positive growth of %, compared with US$ 7891 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Non-Hodgkin Lymphoma Treatment industry is evaluated to reach US$ 12810 million in 2029. The CAGR will be 7.2% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Non-Hodgkin Lymphoma Treatment market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Non-Hodgkin Lymphoma Treatment market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Takeda Pharmaceutical Company Limited
AstraZeneca
Bayer
Novartis AG
Gilead Sciences
Spectrum Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Bristol Myers Squibb Company
Janssen Pharmaceuticals
Roche
CELGENE CORPORATION (Bristol Myers Squibb Company)
Merck & Co., Inc.
Kyowa Kirin Co., Ltd.
AbbVie
Sanofi
Segment by Type
Immunotherapy
Targeted Therapy
Chemotherapy
Others

Segment by Application


Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Non-Hodgkin Lymphoma Treatment introduction, etc. Non-Hodgkin Lymphoma Treatment Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Non-Hodgkin Lymphoma Treatment
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Immunotherapy
1.2.3 Targeted Therapy
1.2.4 Chemotherapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Hodgkin Lymphoma Treatment Market Perspective (2018-2029)
2.2 Global Non-Hodgkin Lymphoma Treatment Growth Trends by Region
2.2.1 Non-Hodgkin Lymphoma Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Non-Hodgkin Lymphoma Treatment Historic Market Size by Region (2018-2024)
2.2.3 Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Region (2024-2029)
2.3 Non-Hodgkin Lymphoma Treatment Market Dynamics
2.3.1 Non-Hodgkin Lymphoma Treatment Industry Trends
2.3.2 Non-Hodgkin Lymphoma Treatment Market Drivers
2.3.3 Non-Hodgkin Lymphoma Treatment Market Challenges
2.3.4 Non-Hodgkin Lymphoma Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Non-Hodgkin Lymphoma Treatment by Players
3.1.1 Global Non-Hodgkin Lymphoma Treatment Revenue by Players (2018-2024)
3.1.2 Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Players (2018-2024)
3.2 Global Non-Hodgkin Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Non-Hodgkin Lymphoma Treatment, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio
3.4.1 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Hodgkin Lymphoma Treatment Revenue in 2022
3.5 Global Key Players of Non-Hodgkin Lymphoma Treatment Head office and Area Served
3.6 Global Key Players of Non-Hodgkin Lymphoma Treatment, Product and Application
3.7 Global Key Players of Non-Hodgkin Lymphoma Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Hodgkin Lymphoma Treatment Breakdown Data by Type
4.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Type (2018-2024)
4.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2024-2029)
5 Non-Hodgkin Lymphoma Treatment Breakdown Data by Application
5.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Application (2018-2024)
5.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
6.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Type
6.2.1 North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024)
6.2.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2024-2029)
6.2.3 North America Non-Hodgkin Lymphoma Treatment Market Share by Type (2018-2029)
6.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Application
6.3.1 North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024)
6.3.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2024-2029)
6.3.3 North America Non-Hodgkin Lymphoma Treatment Market Share by Application (2018-2029)
6.4 North America Non-Hodgkin Lymphoma Treatment Market Size by Country
6.4.1 North America Non-Hodgkin Lymphoma Treatment Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2024)
6.4.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
7.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type
7.2.1 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024)
7.2.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2024-2029)
7.2.3 Europe Non-Hodgkin Lymphoma Treatment Market Share by Type (2018-2029)
7.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application
7.3.1 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024)
7.3.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2024-2029)
7.3.3 Europe Non-Hodgkin Lymphoma Treatment Market Share by Application (2018-2029)
7.4 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country
7.4.1 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2024)
7.4.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
8.2 China Non-Hodgkin Lymphoma Treatment Market Size by Type
8.2.1 China Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024)
8.2.2 China Non-Hodgkin Lymphoma Treatment Market Size by Type (2024-2029)
8.2.3 China Non-Hodgkin Lymphoma Treatment Market Share by Type (2018-2029)
8.3 China Non-Hodgkin Lymphoma Treatment Market Size by Application
8.3.1 China Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024)
8.3.2 China Non-Hodgkin Lymphoma Treatment Market Size by Application (2024-2029)
8.3.3 China Non-Hodgkin Lymphoma Treatment Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
9.2 Asia Non-Hodgkin Lymphoma Treatment Market Size by Type
9.2.1 Asia Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024)
9.2.2 Asia Non-Hodgkin Lymphoma Treatment Market Size by Type (2024-2029)
9.2.3 Asia Non-Hodgkin Lymphoma Treatment Market Share by Type (2018-2029)
9.3 Asia Non-Hodgkin Lymphoma Treatment Market Size by Application
9.3.1 Asia Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024)
9.3.2 Asia Non-Hodgkin Lymphoma Treatment Market Size by Application (2024-2029)
9.3.3 Asia Non-Hodgkin Lymphoma Treatment Market Share by Application (2018-2029)
9.4 Asia Non-Hodgkin Lymphoma Treatment Market Size by Region
9.4.1 Asia Non-Hodgkin Lymphoma Treatment Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2024)
9.4.3 Asia Non-Hodgkin Lymphoma Treatment Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Takeda Pharmaceutical Company Limited
11.1.1 Takeda Pharmaceutical Company Limited Company Details
11.1.2 Takeda Pharmaceutical Company Limited Business Overview
11.1.3 Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Introduction
11.1.4 Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.1.5 Takeda Pharmaceutical Company Limited Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Non-Hodgkin Lymphoma Treatment Introduction
11.2.4 AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.2.5 AstraZeneca Recent Developments
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Non-Hodgkin Lymphoma Treatment Introduction
11.3.4 Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.3.5 Bayer Recent Developments
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Non-Hodgkin Lymphoma Treatment Introduction
11.4.4 Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.4.5 Novartis AG Recent Developments
11.5 Gilead Sciences
11.5.1 Gilead Sciences Company Details
11.5.2 Gilead Sciences Business Overview
11.5.3 Gilead Sciences Non-Hodgkin Lymphoma Treatment Introduction
11.5.4 Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.5.5 Gilead Sciences Recent Developments
11.6 Spectrum Pharmaceuticals
11.6.1 Spectrum Pharmaceuticals Company Details
11.6.2 Spectrum Pharmaceuticals Business Overview
11.6.3 Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
11.6.4 Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.6.5 Spectrum Pharmaceuticals Recent Developments
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Teva Pharmaceutical Industries Ltd. Company Details
11.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.7.3 Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Introduction
11.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments
11.8 Bristol Myers Squibb Company
11.8.1 Bristol Myers Squibb Company Company Details
11.8.2 Bristol Myers Squibb Company Business Overview
11.8.3 Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Introduction
11.8.4 Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.8.5 Bristol Myers Squibb Company Recent Developments
11.9 Janssen Pharmaceuticals
11.9.1 Janssen Pharmaceuticals Company Details
11.9.2 Janssen Pharmaceuticals Business Overview
11.9.3 Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
11.9.4 Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.9.5 Janssen Pharmaceuticals Recent Developments
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche Non-Hodgkin Lymphoma Treatment Introduction
11.10.4 Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.10.5 Roche Recent Developments
11.11 CELGENE CORPORATION (Bristol Myers Squibb Company)
11.11.1 CELGENE CORPORATION (Bristol Myers Squibb Company) Company Details
11.11.2 CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview
11.11.3 CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Introduction
11.11.4 CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.11.5 CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Developments
11.12 Merck & Co., Inc.
11.12.1 Merck & Co., Inc. Company Details
11.12.2 Merck & Co., Inc. Business Overview
11.12.3 Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Introduction
11.12.4 Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.12.5 Merck & Co., Inc. Recent Developments
11.13 Kyowa Kirin Co., Ltd.
11.13.1 Kyowa Kirin Co., Ltd. Company Details
11.13.2 Kyowa Kirin Co., Ltd. Business Overview
11.13.3 Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Introduction
11.13.4 Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.13.5 Kyowa Kirin Co., Ltd. Recent Developments
11.14 AbbVie
11.14.1 AbbVie Company Details
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-Hodgkin Lymphoma Treatment Introduction
11.14.4 AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.14.5 AbbVie Recent Developments
11.15 Sanofi
11.15.1 Sanofi Company Details
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Non-Hodgkin Lymphoma Treatment Introduction
11.15.4 Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
11.15.5 Sanofi Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Immunotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Chemotherapy
Table 5. Key Players of Others
Table 6. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 9. Global Non-Hodgkin Lymphoma Treatment Market Share by Region (2018-2024)
Table 10. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Non-Hodgkin Lymphoma Treatment Market Share by Region (2024-2029)
Table 12. Non-Hodgkin Lymphoma Treatment Market Trends
Table 13. Non-Hodgkin Lymphoma Treatment Market Drivers
Table 14. Non-Hodgkin Lymphoma Treatment Market Challenges
Table 15. Non-Hodgkin Lymphoma Treatment Market Restraints
Table 16. Global Non-Hodgkin Lymphoma Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 17. Global Non-Hodgkin Lymphoma Treatment Revenue Share by Players (2018-2024)
Table 18. Global Top Non-Hodgkin Lymphoma Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2022)
Table 19. Global Non-Hodgkin Lymphoma Treatment Industry Ranking 2021 VS 2022 VS 2024
Table 20. Global 5 Largest Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 21. Global Key Players of Non-Hodgkin Lymphoma Treatment, Headquarters and Area Served
Table 22. Global Key Players of Non-Hodgkin Lymphoma Treatment, Product and Application
Table 23. Global Key Players of Non-Hodgkin Lymphoma Treatment, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 26. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2018-2024)
Table 27. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2024-2029)
Table 29. Global Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 30. Global Non-Hodgkin Lymphoma Treatment Revenue Share by Application (2018-2024)
Table 31. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Non-Hodgkin Lymphoma Treatment Revenue Share by Application (2024-2029)
Table 33. North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 34. North America Non-Hodgkin Lymphoma Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 36. North America Non-Hodgkin Lymphoma Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Non-Hodgkin Lymphoma Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 39. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 41. Europe Non-Hodgkin Lymphoma Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 43. Europe Non-Hodgkin Lymphoma Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Non-Hodgkin Lymphoma Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 46. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 48. China Non-Hodgkin Lymphoma Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 50. China Non-Hodgkin Lymphoma Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 52. Asia Non-Hodgkin Lymphoma Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 54. Asia Non-Hodgkin Lymphoma Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Non-Hodgkin Lymphoma Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 57. Asia Non-Hodgkin Lymphoma Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 65. Takeda Pharmaceutical Company Limited Company Details
Table 66. Takeda Pharmaceutical Company Limited Business Overview
Table 67. Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Product
Table 68. Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 69. Takeda Pharmaceutical Company Limited Recent Developments
Table 70. AstraZeneca Company Details
Table 71. AstraZeneca Business Overview
Table 72. AstraZeneca Non-Hodgkin Lymphoma Treatment Product
Table 73. AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 74. AstraZeneca Recent Developments
Table 75. Bayer Company Details
Table 76. Bayer Business Overview
Table 77. Bayer Non-Hodgkin Lymphoma Treatment Product
Table 78. Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 79. Bayer Recent Developments
Table 80. Novartis AG Company Details
Table 81. Novartis AG Business Overview
Table 82. Novartis AG Non-Hodgkin Lymphoma Treatment Product
Table 83. Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 84. Novartis AG Recent Developments
Table 85. Gilead Sciences Company Details
Table 86. Gilead Sciences Business Overview
Table 87. Gilead Sciences Non-Hodgkin Lymphoma Treatment Product
Table 88. Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 89. Gilead Sciences Recent Developments
Table 90. Spectrum Pharmaceuticals Company Details
Table 91. Spectrum Pharmaceuticals Business Overview
Table 92. Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product
Table 93. Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 94. Spectrum Pharmaceuticals Recent Developments
Table 95. Teva Pharmaceutical Industries Ltd. Company Details
Table 96. Teva Pharmaceutical Industries Ltd. Business Overview
Table 97. Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Product
Table 98. Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 99. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 100. Bristol Myers Squibb Company Company Details
Table 101. Bristol Myers Squibb Company Business Overview
Table 102. Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Product
Table 103. Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 104. Bristol Myers Squibb Company Recent Developments
Table 105. Janssen Pharmaceuticals Company Details
Table 106. Janssen Pharmaceuticals Business Overview
Table 107. Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product
Table 108. Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 109. Janssen Pharmaceuticals Recent Developments
Table 110. Roche Company Details
Table 111. Roche Business Overview
Table 112. Roche Non-Hodgkin Lymphoma Treatment Product
Table 113. Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 114. Roche Recent Developments
Table 115. CELGENE CORPORATION (Bristol Myers Squibb Company) Company Details
Table 116. CELGENE CORPORATION (Bristol Myers Squibb Company) Business Overview
Table 117. CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Product
Table 118. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 119. CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Developments
Table 120. Merck & Co., Inc. Company Details
Table 121. Merck & Co., Inc. Business Overview
Table 122. Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Product
Table 123. Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 124. Merck & Co., Inc. Recent Developments
Table 125. Kyowa Kirin Co., Ltd. Company Details
Table 126. Kyowa Kirin Co., Ltd. Business Overview
Table 127. Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Product
Table 128. Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 129. Kyowa Kirin Co., Ltd. Recent Developments
Table 130. AbbVie Company Details
Table 131. AbbVie Business Overview
Table 132. AbbVie Non-Hodgkin Lymphoma Treatment Product
Table 133. AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 134. AbbVie Recent Developments
Table 135. Sanofi Company Details
Table 136. Sanofi Business Overview
Table 137. Sanofi Non-Hodgkin Lymphoma Treatment Product
Table 138. Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2024) & (US$ Million)
Table 139. Sanofi Recent Developments
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Non-Hodgkin Lymphoma Treatment Market Share by Type: 2022 VS 2029
Figure 3. Immunotherapy Features
Figure 4. Targeted Therapy Features
Figure 5. Chemotherapy Features
Figure 6. Others Features
Figure 7. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Non-Hodgkin Lymphoma Treatment Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Online Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Non-Hodgkin Lymphoma Treatment Report Years Considered
Figure 14. Global Non-Hodgkin Lymphoma Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Non-Hodgkin Lymphoma Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Non-Hodgkin Lymphoma Treatment Market Share by Region: 2022 VS 2029
Figure 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Players in 2022
Figure 18. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue in 2022
Figure 20. North America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Non-Hodgkin Lymphoma Treatment Market Share by Type (2018-2029)
Figure 22. North America Non-Hodgkin Lymphoma Treatment Market Share by Application (2018-2029)
Figure 23. North America Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 24. United States Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Non-Hodgkin Lymphoma Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Non-Hodgkin Lymphoma Treatment Market Share by Type (2018-2029)
Figure 28. Europe Non-Hodgkin Lymphoma Treatment Market Share by Application (2018-2029)
Figure 29. Europe Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 30. Germany Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Non-Hodgkin Lymphoma Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Non-Hodgkin Lymphoma Treatment Market Share by Type (2018-2029)
Figure 38. China Non-Hodgkin Lymphoma Treatment Market Share by Application (2018-2029)
Figure 39. Asia Non-Hodgkin Lymphoma Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Non-Hodgkin Lymphoma Treatment Market Share by Type (2018-2029)
Figure 41. Asia Non-Hodgkin Lymphoma Treatment Market Share by Application (2018-2029)
Figure 42. Asia Non-Hodgkin Lymphoma Treatment Market Share by Region (2018-2029)
Figure 43. Japan Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)
Figure 53. Brazil Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 60. AstraZeneca Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 61. Bayer Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 62. Novartis AG Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 63. Gilead Sciences Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 64. Spectrum Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 65. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 66. Bristol Myers Squibb Company Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 67. Janssen Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 68. Roche Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 69. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 70. Merck & Co., Inc. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 71. Kyowa Kirin Co., Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 72. AbbVie Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 73. Sanofi Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2024)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed